forum comments

OBR Daily Commentary

Bayer to Showcase New Data from its Growing Cancer Portfolio at 2019 ASCO GU Cancers Symposium

(Bayer) Feb 5, 2019 - First presentation of data from the pivotal Phase III ARAMIS trial with the investigational compound darolutamide in patients with non-metastatic castration-resistant prostate cancer.

Read Article

Tomasz M. Beer, MD, FACP (Posted: February 05, 2019)

Daralutamide would be the third agent with demonstrated efficacy in non-metastatic castration resistant prostate cancer if the ARAMIS trial yields positive results. Both efficacy and safety data will be of interest and clinicians evaluate a growing stable of options in this disease state where enzalutamide and apalutamide have been approved.

Add Comment 1 Comment(s)

Meet the Editorial Board

Prostate Cancer

Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

OBR Daily Commentary

Bayer to Showcase New Data from its Growing Cancer Portfolio at 2019 ASCO GU Cancers Symposium

Meet the Editorial Board

Prostate Cancer

Tomasz M. Beer, MD, FACP

Community Oncology

Dean Gesme, MD

Breast Cancer

Debu Tripathy, MD

Lung Cancer

H. Jack West, MD

Gastrointestinal Cancers

Howard S. Hochster, MD

Radiation Oncology

Howard Sandler, MD, MS, FASTRO

Community Oncology

Jeff Patton, M.D.

Precision Medicine Section Editor

Jennifer Levin Carter, MD, MPH

Financial Sector

Michael G. King Jr.

Gastrointestinal Cancers

Richard Goldberg, MD

Editor-In-Chief

Robert A. Figlin, MD., FACP

Health Policy

Ted Okon

Community Oncology

Thomas Marsland, MD

Community Oncology

William Harwin MD

Health Policy

William McGivney, PhD

Payer

Winston Wong, PharmD